{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:30:10Z","timestamp":1793089810503,"version":"4.5.0"},"reference-count":124,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2018.4287","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T07:56:30Z","timestamp":1519718190000},"source":"Crossref","is-referenced-by-count":207,"title":["Cutaneous melanoma: From pathogenesis to therapy (Review)"],"prefix":"10.3892","author":[{"given":"Giulia","family":"Leonardi","sequence":"first","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Falzone","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Salemi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Zangh\u00ef\u00bf\u00bd","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences and Advanced Technology \u2018G.F. Ingrassia\u2019, University of Catania, 95125 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Spandidos","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mccubrey","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Candido","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Libra","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"key20200713184557_b1-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","article-title":"Melanoma epidemiology, biology and prognosis","volume":"11","author":"Ali","year":"2013","journal-title":"EJC Suppl"},{"key":"key20200713184557_b2-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"key20200713184557_b3-ijo-52-04-1071","first-page":"1005","article-title":"Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"key20200713184557_b4-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJM199904293401707","article-title":"The pathogenesis of melanoma induced by ultraviolet radiation","volume":"340","author":"Gilchrest","year":"1999","journal-title":"N Engl J Med"},{"key":"key20200713184557_b5-ijo-52-04-1071","first-page":"291","article-title":"Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks","volume":"9","author":"Pennello","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20200713184557_b6-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.3892\/mmr.2016.5791","article-title":"Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review)","volume":"14","author":"Falzone","year":"2016","journal-title":"Mol Med Rep"},{"key":"key20200713184557_b7-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1289\/ehp.93101252","article-title":"Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals","volume":"101","author":"Nelemans","year":"1993","journal-title":"Environ Health Perspect"},{"key":"key20200713184557_b8-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R","article-title":"Melanoma and sun exposure: An overview of published studies","volume":"73","author":"Elwood","year":"1997","journal-title":"Int J Cancer"},{"key":"key20200713184557_b9-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3892\/or.2014.2977","article-title":"Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure","volume":"31","author":"Candido","year":"2014","journal-title":"Oncol Rep"},{"key":"key20200713184557_b10-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"key20200713184557_b11-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/oxfordjournals.aje.a117092","article-title":"Case-control study of malignant melanoma in Washington state. I. Constitutional factors and sun exposure","volume":"139","author":"White","year":"1994","journal-title":"Am J Epidemiol"},{"key":"key20200713184557_b12-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1055-9965.EPI-09-1249","article-title":"Indoor tanning and risk of melanoma: A case-control study in a highly exposed population","volume":"19","author":"Lazovich","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 3","key":"key20200713184557_b13-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20200713184557_b14-ijo-52-04-1071","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/ijc.22453","article-title":"The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review","volume":"120","author":"International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer","year":"2007","journal-title":"Int J Cancer"},{"key":"key20200713184557_b15-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jamadermatol.2013.6896","article-title":"International prevalence of indoor tanning: A systematic review and meta-analysis","volume":"150","author":"Wehner","year":"2014","journal-title":"JAMA Dermatol"},{"key":"key20200713184557_b16-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1034\/j.1600-0749.2003.00047.x","article-title":"Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data","volume":"16","author":"Bauer","year":"2003","journal-title":"Pigment Cell Res"},{"key":"key20200713184557_b17-ijo-52-04-1071","first-page":"1481","article-title":"Melanoma: Molecular pathogenesis and emerging target therapies (Review)","volume":"34","author":"Russo","year":"2009","journal-title":"Int J Oncol"},{"key":"key20200713184557_b18-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.seminoncol.2016.08.003","article-title":"Genetic predisposition to melanoma","volume":"43","author":"Hawkes","year":"2016","journal-title":"Semin Oncol"},{"key":"key20200713184557_b19-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/archderm.139.12.1620","article-title":"Cutaneous melanomas associated with nevi","volume":"139","author":"Bevona","year":"2003","journal-title":"Arch Dermatol"},{"key":"key20200713184557_b20-ijo-52-04-1071","first-page":"682","article-title":"Dysplastic nevi and other risk markers for melanoma","volume":"23","author":"Seykora","year":"1996","journal-title":"Semin Oncol"},{"key":"key20200713184557_b21-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1097\/01.PRS.0000122209.10277.2A","article-title":"Risk of melanoma arising in large congenital melanocytic nevi: A systematic review","volume":"113","author":"Watt","year":"2004","journal-title":"Plast Reconstr Surg"},{"key":"key20200713184557_b22-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2004.10.015","article-title":"Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"key20200713184557_b23-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/ijc.24011","article-title":"Nevus density and melanoma risk in women: A pooled analysis to test the divergent pathway hypothesis","volume":"124","author":"Olsen","year":"2009","journal-title":"Int J Cancer"},{"key":"key20200713184557_b24-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1751-1097.2011.00970.x","article-title":"Melanocortin 1 receptor variants: Functional role and pigmentary associations","volume":"87","author":"Dessinioti","year":"2011","journal-title":"Photochem Photobiol"},{"key":"key20200713184557_b25-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/archderm.137.11.1493","article-title":"Genetic epidemiology of cutaneous melanoma: A global perspective","volume":"137","author":"Goldstein","year":"2001","journal-title":"Arch Dermatol"},{"key":"key20200713184557_b26-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.08.038","article-title":"Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome","volume":"74","author":"Soura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key20200713184557_b27-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ng0795-351","article-title":"Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds","volume":"10","author":"Gruis","year":"1995","journal-title":"Nat Genet"},{"key":"key20200713184557_b28-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ng0196-97","article-title":"Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma","volume":"12","author":"Zuo","year":"1996","journal-title":"Nat Genet"},{"key":"key20200713184557_b29-ijo-52-04-1071","first-page":"390","article-title":"Anatomy, histology and immunohistochemistry of normal human skin","volume":"12","author":"Kanitakis","year":"2002","journal-title":"Eur J Dermatol"},{"key":"key20200713184557_b30-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nature05660","article-title":"Melanocyte biology and skin pigmentation","volume":"445","author":"Lin","year":"2007","journal-title":"Nature"},{"key":"key20200713184557_b31-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"key20200713184557_b32-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"key20200713184557_b33-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20200713184557_b34-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"key20200713184557_b35-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-017-0112-5","article-title":"Ageing: From inflammation to cancer","volume":"15","author":"Leonardi","year":"2018","journal-title":"Immun Ageing"},{"key":"key20200713184557_b36-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1755-148X.2010.00799.x","article-title":"Immune reactions in benign and malignant melanocytic lesions: Lessons for immunotherapy","volume":"24","author":"Speeckaert","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20200713184557_b37-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"key20200713184557_b38-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0046-8177(96)90157-4","article-title":"Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists","volume":"27","author":"Farmer","year":"1996","journal-title":"Hum Pathol"},{"key":"key20200713184557_b39-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CMR.0000000000000235","article-title":"Endothelin-1 in the tumor microenvironment correlates with melanoma invasion","volume":"26","author":"Chiriboga","year":"2016","journal-title":"Melanoma Res"},{"key":"key20200713184557_b40-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejcb.2014.01.002","article-title":"Metalloproteinases in melanoma","volume":"93","author":"Moro","year":"2014","journal-title":"Eur J Cell Biol"},{"key":"key20200713184557_b41-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.phrs.2016.07.017","article-title":"Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation","volume":"111","author":"Sandri","year":"2016","journal-title":"Pharmacol Res"},{"key":"key20200713184557_b42-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"933","DOI":"10.18632\/aging.100951","article-title":"MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma","volume":"8","author":"Falzone","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"key20200713184557_b43-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.3892\/or.2014.3103","article-title":"Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via downregulation of NF-\u03baB signaling pathway","volume":"31","author":"Lee","year":"2014","journal-title":"Oncol Rep"},{"key":"key20200713184557_b44-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3892\/or.2017.5362","article-title":"NF-\u03baB inhibition is associated with OPN\/MMP 9 downregulation in cutaneous melanoma","volume":"37","author":"Guarneri","year":"2017","journal-title":"Oncol Rep"},{"key":"key20200713184557_b45-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"key20200713184557_b46-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Cancer Genome Atlas Network: Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"key20200713184557_b47-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"key20200713184557_b48-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat Genet"},{"key":"key20200713184557_b49-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget"},{"key":"key20200713184557_b50-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","article-title":"The RAF proteins take centre stage","volume":"5","author":"Wellbrock","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200713184557_b51-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/sj.onc.1210392","article-title":"Differential regulation and properties of MAPKs","volume":"26","author":"Raman","year":"2007","journal-title":"Oncogene"},{"key":"key20200713184557_b52-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.critrevonc.2015.08.021","article-title":"Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma","volume":"96","author":"Carlino","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20200713184557_b53-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: Variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"key20200713184557_b54-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/PPO.0b013e31824d448c","article-title":"The role of the PI3K-AKT pathway in melanoma","volume":"18","author":"Davies","year":"2012","journal-title":"Cancer J"},{"key":"key20200713184557_b55-ijo-52-04-1071","first-page":"3728","article-title":"Mitogen-actived protein kinase activation is an early event in melanoma progression","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20200713184557_b56-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-07-0665","article-title":"Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1","volume":"13","author":"Wang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20200713184557_b57-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"e35309","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PLoS One"},{"key":"key20200713184557_b58-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"Rubinstein","year":"2010","journal-title":"J Transl Med"},{"key":"key20200713184557_b59-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"key20200713184557_b60-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"key20200713184557_b61-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/bjd.15436","article-title":"Beyond the BRAFV600E hotspot: Biology and clinical implications of rare BRAF gene mutations in melanoma patients","volume":"177","author":"Richtig","year":"2017","journal-title":"Br J Dermatol"},{"key":"key20200713184557_b62-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"key20200713184557_b63-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1515\/BC.2005.025","article-title":"Oncogenic Ras in tumour progression and metastasis","volume":"386","author":"Giehl","year":"2005","journal-title":"Biol Chem"},{"key":"key20200713184557_b64-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: Biological behavior and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"key":"key20200713184557_b65-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1 in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov"},{"key":"key20200713184557_b66-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","article-title":"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition","volume":"3","author":"Whittaker","year":"2013","journal-title":"Cancer Discov"},{"key":"key20200713184557_b67-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713184557_b68-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat Genet"},{"key":"key20200713184557_b69-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-13-0017","article-title":"An unholy alliance: Cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance","volume":"3","author":"Gibney","year":"2013","journal-title":"Cancer Discov"},{"key":"key20200713184557_b70-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20200713184557_b71-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1755-148X.2010.00671.x","article-title":"Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure","volume":"23","author":"Handolias","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20200713184557_b72-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713184557_b73-ijo-52-04-1071","first-page":"4868","article-title":"CDKN2A\/16 is inactivated in most melanoma cell lines","volume":"57","author":"Castellano","year":"1997","journal-title":"Cancer Res"},{"key":"key20200713184557_b74-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1038\/sj.onc.1206461","article-title":"The INK4a\/ARF locus and melanoma","volume":"22","author":"Sharpless","year":"2003","journal-title":"Oncogene"},{"key":"key20200713184557_b75-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"key20200713184557_b76-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-06-0384","article-title":"Epigenetic silencing of the PTEN gene in melanoma","volume":"66","author":"Mirmohammadsadegh","year":"2006","journal-title":"Cancer Res"},{"key":"key20200713184557_b77-ijo-52-04-1071","first-page":"2881","article-title":"Loss of PTEN promotes tumor development in malignant melanoma","volume":"63","author":"Stahl","year":"2003","journal-title":"Cancer Res"},{"key":"key20200713184557_b78-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":"Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma","volume":"122","author":"Tsao","year":"2004","journal-title":"J Invest Dermatol"},{"key":"key20200713184557_b79-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1038\/onc.2010.349","article-title":"Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis","volume":"29","author":"Nogueira","year":"2010","journal-title":"Oncogene"},{"key":"key20200713184557_b80-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"key20200713184557_b81-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ccr.2011.10.030","article-title":"\u03b2-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas","volume":"20","author":"Damsky","year":"2011","journal-title":"Cancer Cell"},{"key":"key20200713184557_b82-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0002-9440(10)65278-9","article-title":"Frequent nuclear\/cytoplasmic localization of \u03b2-catenin without exon 3 mutations in malignant melanoma","volume":"154","author":"Rimm","year":"1999","journal-title":"Am J Pathol"},{"key":"key20200713184557_b83-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jso.21962","article-title":"Evidence-based treatment of early-stage melanoma","volume":"104","author":"Ross","year":"2011","journal-title":"J Surg Oncol"},{"key":"key20200713184557_b84-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713184557_b85-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"key20200713184557_b86-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"key20200713184557_b87-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20200713184557_b88-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713184557_b89-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713184557_b90-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"key20200713184557_b91-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20200713184557_b92-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20200713184557_b93-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20200713184557_b94-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3892\/or.2014.3275","article-title":"Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)","volume":"32","author":"Malas","year":"2014","journal-title":"Oncol Rep"},{"key":"key20200713184557_b95-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3892\/ol.2015.3296","article-title":"Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"key20200713184557_b96-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3892\/ijo.2016.3586","article-title":"Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells","volume":"49","author":"Akiyama","year":"2016","journal-title":"Int J Oncol"},{"key":"key20200713184557_b97-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"key20200713184557_b98-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"e0139438","DOI":"10.1371\/journal.pone.0139438","article-title":"Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA 4 antibodies: Association with overall survival","volume":"10","author":"Mangana","year":"2015","journal-title":"PLoS One"},{"key":"key20200713184557_b99-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713184557_b100-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/1547691X.2012.678021","article-title":"Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1","volume":"9","author":"Simeone","year":"2012","journal-title":"J Immunotoxicol"},{"key":"key20200713184557_b101-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20200713184557_b102-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/jcp.22647","article-title":"Therapeutic resistance resulting from mutations in Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR signaling pathways","volume":"226","author":"McCubrey","year":"2011","journal-title":"J Cell Physiol"},{"key":"key20200713184557_b103-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"192","DOI":"10.18632\/aging.100296","article-title":"Roles of the Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging","volume":"3","author":"Steelman","year":"2011","journal-title":"Aging (Albany NY)"},{"key":"key20200713184557_b104-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"key20200713184557_b105-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"key20200713184557_b106-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"key20200713184557_b107-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"key20200713184557_b108-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF Mutation status in circulating-free dna and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials","volume":"22","author":"Santiago-Walker","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20200713184557_b109-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discov"},{"key":"key20200713184557_b110-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"key20200713184557_b111-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-16-3172","article-title":"Acquired immune resistance follows complete tumor regression without loss of target antigens or IFN\u03b3 signaling","volume":"77","author":"Donia","year":"2017","journal-title":"Cancer Res"},{"key":"key20200713184557_b112-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"key20200713184557_b113-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Disco"},{"key":"key20200713184557_b114-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD 1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"key20200713184557_b115-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fphar.2017.00603","article-title":"Lactobacillus rhamnosus GG: An overview to explore the rationale of its use in cancer","volume":"1","author":"Banna","year":"2017","journal-title":"Front Pharmacol"},{"key":"key20200713184557_b116-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"key20200713184557_b117-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"key20200713184557_b118-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"e0152104","DOI":"10.1371\/journal.pone.0152104","article-title":"Computational modeling of PI3K\/AKT and MAPK signaling pathways in melanoma Cancer","volume":"11","author":"Pappalardo","year":"2016","journal-title":"PLoS One"},{"key":"key20200713184557_b119-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.celrep.2015.09.037","article-title":"New functional signatures for understanding melanoma biology from tumor cell lineage-specific analysis","volume":"13","author":"Rambow","year":"2015","journal-title":"Cell Reports"},{"key":"key20200713184557_b120-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/17460441.2016.1174688","article-title":"Computational modeling in melanoma for novel drug discovery","volume":"11","author":"Pennisi","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"key20200713184557_b121-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200713184557_b122-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200713184557_b123-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"key20200713184557_b124-ijo-52-04-1071","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T15:49:41Z","timestamp":1719848981000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2018.4287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":124,"URL":"https:\/\/doi.org\/10.3892\/ijo.2018.4287","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]}}}